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Abstract
Background—Arterial hypertension is a major risk factor that can lead to complication of
peripheral vascular disease due, in part, to endothelial dysfunction. Because sodium nitrite (SN)
can be converted to nitric oxide (NO), which counteracts endothelial dysfunction, we explored the
effect of nitrite on neovascularization following hind-limb ischemia in different models of
hypertension (HT).
Methods and results—Chronic delivery of angiotensin-II (Ang-II, 400ng/Kg/min) or
N(omega)-nitro-L-arginine-methyl-ester (L-NAME, 0.1g/L) were used for a two week period to
induce hypertension. Mice were subjected to femoral artery ligation induced-ischemia in the hind-
limb followed by treatment with SN (50mg/L) for 2-weeks. SN significantly reduced systolic
arterial blood pressure in mice receiving Ang-II and L-NAME, but had no effect in sham animals.
After 2 weeks, blood flow and microangiography showed 60%±1.0 recovery in sham compared to
40%±1.3 in HT mice. Importantly, sham and HT mice treated with SN showed a 100% blood flow
recovery associated with normalization in capillary density. The inhibition of xanthine-oxido-
reductase (allopurinol) or VEGFR (SU-5416) prevented the neovascularization in HT mice treated
with SN. Cyclic GMP (cGMP) content in the hind-limb was significantly increased in mice treated
with SN compared to non-treated mice. Nitrite/nitrate content was only increased in the sham
group treated with SN. Immunoprecipitation and Western blot analysis revealed an increase in
eNOS/Akt/VEGFR phosphorylation in skeletal muscle from mice treated with SN compared to
non-treated mice.
Conclusion—Our findings indicate that SN therapy rescues the neovascularization and blood
flow recovery in ischemic hind-limb of sham and HT mice likely through the Akt/NO/cGMP and
VEGFR pathways.
#Corresponding Authors: Khalid Matrougui, Ph.D. (kmatroug@tulane.edu), Department of Physiology, Hypertension and Renal
Center of Excellence, Tulane University, 1430 Tulane Ave, New Orleans LA-70112. Phone-(504)-889-2588, Fax-(504)-988-2675.
Disclosures
None.
NIH Public Access
Author Manuscript
Pflugers Arch. Author manuscript; available in PMC 2013 December 01.
Published in final edited form as:
Pflugers Arch. 2012 December ; 464(6): 583–592. doi:10.1007/s00424-012-1167-y.
$watermark-text
$watermark-text
$watermark-text
Keywords
Hypertension; neovascularization; ischemia; Angiotensin II; L-NAME; sodium nitrite; peripheral
ischemia
Introduction
Arterial hypertension is a major risk factor that can lead to complication of peripheral
vascular disease.[35] Previous studies showed that hypertension in human and animal
models is associated with endothelial dysfunction and microvascular rarefaction.[2] These
data suggest that hypertension contributes to alterations of vascular growth patterns.
Therefore, understanding the pathophysiological mechanisms regulating angiogenesis would
provide valuable insight into mechanisms of therapeutic angiogenesis for preventing or
treating chronic tissue ischemia that occurs in cardiovascular diseases such hypertension.
Nitric oxide (NO) is produced by NO-synthase (NOSs) in the endothelium and regulates
vascular reactivity,[29] which is altered in hypertension.[37] NO is also critical in
angiogenesis, as evidenced by the reduction in angiogenesis in mice lacking the gene
encoding for eNOS and, the enhanced angiogenesis response in animals treated with NO
donors.[5,13,40] Vascular endothelial growth factor (VEGF) regulates many cellular and
molecular events in the neovascularization process such endothelial cells migration and
proliferation.[11,30] It is well known that shear stress releases NO, which is also an
important factor in the mechanism of angiogenesis. Moreover, there are reciprocal
interactions between VEGF and NO in the mechanisms of angiogenesis.[57,12]
Nitrite has previously been used as a marker of NO formation in tissues and plasma.[13,26]
Recently nitrite was recognized as a beneficial storage form of NO in blood and tissues that
initiates rapidly reduced to NO that initiates cytoprotective signaling in pathological states
like kidney ischemia/reperfusion injury.[54,40] Recent studies described the ability of nitrite
to enhance angiogenesis in the ischemic hind-limb of normotensive mice.[32] Since our goal
is to determine the role of nitrite therapy in impaired angiogenesis related to deficiency of
NO associated with hypertension, we chose models of hypertension where NO pathway is
impaired. It has been shown by our group and others that mice infused with angiotension II
or L-NAME display a significant impairment in NO pathway. Therefore, to accomplish our
goal, we infused mice with angiotensin II or L-NAME to induce hypertension with
impairment in NO pathway and angiogenesis. In these models, we test the hypothesis that
sodium nitrite therapy would enhance ischemia-induced angiogenesis.
Methods
Animal Model and Surgery
Sixty male C57BL/6J (8–10 weeks old) were used in the present study. These studies are
conformed to the principles of the National Institutes of Health “Guide for the Care and Use
of Laboratory Animals” and the Tulane University Institutional Animal Care approved the
protocol. Mice were infused with Ang II (400 ng/kg/min)[21] or received L-NAME (100
mg/L) for two weeks.[32] Then hind-limb ischemia model was induced in the following
groups by ligation of the proximal part of the left femoral artery, as previously described
[32,49,3] for two weeks in: 1) sham; 2) sham + sodium nitrite (50 mg/L in the drinking
water) [51]; 3) L-NAME (eNOS inhibitor); 4) L-NAME (in the drinking water) + sodium
nitrite ± (allopurinol “xanthine oxidase” or SU-5416 “VEGFR inhibitor” dissolved in
DMSO); 5) Ang II (mini-osmotic pump); and 6) Ang II + sodium nitrite ± (allopurinol or
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SU-5416 i.p. injection). Hypertension and hind-limb ischemia were induced on the same day
and lasted for a period of two weeks.
Blood Pressure
Systolic Blood Pressure (SBP) was measured by tail-cuff plethysmography (Softron,
BP-98A), before treatment and then once a week as previously described.[21] All mice were
trained to the tail cuff measurements one week before starting experiments. Measurements
were performed at the same time, always at 10 am the morning, with the same number of
measurements (10 trials) for a particular single measurement. The temperature at the time of
measurement was the same for all groups of mice. The tail cuff procedure accurately
measures SBP but underestimates diastolic blood pressure. Also, changes in time of day;
ambient conditions; operator handling of each animal; or subtle behavioral differences
between groups, strains, or individual animals can introduce experimental variability to the
measurement.
Laser Doppler Measurement of Hind-limb Blood Flow
Hind-limb blood flow measurements over the region of interest were performed before
surgery, immediately after surgery, and serially over 2 weeks with a MoorLDI-Laser (Moor
Instruments). The blood flow of right and left hind-limbs was assess by scanning the same
lower abdomen and limbs of the mice with a laser Doppler blood flow meter as previously
reported.[3,50]
X-Ray Quantification of Hind-limb Angiogenesis
Vessel density was assessed by high-definition microangiography at the end of the treatment
period, as previously described.[3,25] Briefly, mice were anesthetized and contrast media
(barium sulfate, 1 g/mL) was injected through a catheter introduced into the abdominal
aorta. Vessel density quantification was determined using Multi Gauge – FUJIFILM.
Immunoprecipitation and Western Blot Analysis
Immunoprecipitation and Western blot analysis was performed as previously described.
[3,7,8,52] We used Western blot analysis to assess the phosphorylation and total levels of
Akt, eNOS and VEGFR, in the ischemic and non-ischemic hind-limb, using specific
antibodies anti-eNOS or anti-Akt or anti-VEGFR antibodies at the dilution (1:1000). The
quantification of Western blot was determined using Fujifilm-Multi Gauge software.
Colorimetric Determination of Nitrite, Nitrate and cGMP
Nitrite, Nitrate and cGMP levels were measured in hind-limb muscle from all mice. The
mice were sacrificed, the hind-limb muscles were immediately harvested and snap frozen in
liquid nitrogen. The cGMP measurements were performed using a sandwich enzyme-linked
immunosorbent assay (ELISA; Cayman Chemical, Ann Arbor, MI) according to the
manufacturer instructions and as previously described.[48,43] Sham values were considered
as 100%. All data from other groups were normalized to the sham values. For nitrite and
nitrate measurements, we used chemiluminescence as previously described.[32]
Immunohistochemistry
Immunohistochemistry was performed as previously described.[3,7,52,6] Hind-limb tissues
were stained with α-actin, von Willebrand factor (Cell signaling) antibodies, and secondary
rabbit anti mouse coupled to Alexa Fluor (Molecular Probes). Cellular nuclei were
counterstained with DAPI (Molecular Probes). After two weeks, mice were anesthetized and
perfused with formalin for 45 min. Hind-limb muscles were then harvested, sectioned at 5
μm using a cryostat and mounted on slides for immunohistochemistry. We used primary
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antibodies: rabbit polyclonal anti-human factor VIII (DAKO) to detect endothelial cells;
mouse monoclonal anti-smooth muscle actin (clone 1A4; Sigma) to detect smooth muscle
cells. Goat anti-mouse and chicken anti-rabbit Alexa-Fluor 594 antibodies were used as
secondary antibodies. The capillary density was then determined by counting the number of
capillaries in each section of muscle.
Antibodies
Phosphorylated VEGF receptor 2 (Tyr951, dilution 1:1000), total VEGF receptor, total Akt,
phosphorylated Akt (Ser476, dilution 1:1000), total eNOS, phosphorylated eNOS (Ser1177,
dilution 1:1000), von Willebrand factor (dilution 1:1000) and α-smooth muscle actin
(dilution 1:1000) were purchased from Sigma, Cell Signaling Technology and Promega.
Statistical Analysis
Results are expressed as mean ± SEM. Comparisons between groups in term of systolic
blood pressure, blood flow, vascular density, staining cumulative data, cGMP, nitrite and
nitrate in the tissue and Western blot analysis data were analyzed by using posthoc
Bonferroni t tests and Student’s t test with a minimum of P< 0.05 to reach significance. Also
One-way or 2-way ANOVA was used to compare each parameter when there were 2
independent groups. Values of P<0.05 were considered significant.
RESULTS
Effects of Sodium Nitrite on Systolic Blood Pressure
Systolic blood pressure was increased significantly in mice receiving angiotensin II (Ang II)
infusion or L-NAME treatment compared to sham. Hypertensive mice treated with sodium
nitrite (SN) had significantly reduced systolic blood pressure (Figure 1). The treatment of
sham animal with SN did not alter systolic blood pressure (Figure 1).
Effects of Sodium Nitrite on Blood Flow Recovery in Ischemic Hind-limb from
Normotensive and Hypertensive Mice
Blood flow was assessed by Doppler-flow before, just after surgery, and then once a week
for two weeks in sham ± SN, L-NAME ± SN and Ang II ± SN mice (Fig. 2A&B). After
femoral artery ligation, blood flow was significantly reduced to less than 2% of the value
before ligation in all groups associated with a problem in hind-limb movement within the
first two days. After two weeks, blood flow was significantly lower in the ischemic hind-
limb from hypertensive mice compared to sham (Figure 2). Interestingly, as shown in Figure
2B, quantitative analysis of the laser Doppler imaging revealed a significant increase in
blood flow recovery in the ischemic hind-limb from hypertensive and normotensive mice
treated with SN in comparison with non treated mice.
The inhibition of xanthine-oxido-reductase (allopurinol, 100 mg/kg, i.p.) or the VEGFR
(SU-5416, 50 mg/kg, i.p.) prevented recovery of flow in the ischemic hind-limb of
hypertensive mice treated with sodium nitrite (Figure 2C, D).
Effects of Sodium Nitrite on Blood Vessel Density in Ischemic Hind-limb from
Normotensive and Hypertensive Mice
Vessel density was evaluated by high-definition microangiography at the end of the
treatment period. We injected contrast media (barium sulfate, 1 g/ml) into the abdominal
aorta, and angiogram from the right and left hind-limbs were then examined using digital X-
ray (Fig. 3). After two weeks, vessel density in sham mice was significantly lower in the
ischemic hind-limb compared to the non-ischemic hind-limb. However, in sham treated with
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SN, the ischemic hind-limb vessel density was not changed compared to non-ischemic hind-
limb. In the group receiving L-NAME or Ang II, vessel density was reduced compared to
sham (Figure 3). Mice treated with L-NAME or Ang II and then treated with SN displayed a
similar pattern vessel density compared to sham mice (Figure 3).
Effects of Sodium Nitrite on Capillary Density in Ischemic Hind-limb from Normotensive
and Hypertensive Mice
Blood flow and micro-angiographic data were confirmed by capillary density analysis using
Von Willebrand factor staining at the end of the treatment period (Figure 4A,B). Data
showed a significant reduction in Von Willebrand factor staining in hypertensive mice,
which was rescued with SN treatment (Figure 4A,B). Capillary density was reduced in the
ischemic hind-limb from hypertensive mice compared to sham (Figure 4C). Sham and
hypertensive mice treated with SN displayed significant increases in capillary density
compared to non-treated mice (Figure 4C).
Effects of Sodium Nitrite on cGMP and Nitrite/Nitrate Content in Ischemic Hind-limb from
Normotensive and Hypertensive Mice
Colorimetric determination of nitrite, nitrate and cGMP analysis in hind-limb ischemic
muscle lysates was performed in all groups. The content of cGMP was decreased in
ischemic hind-limb from mice receiving L-NAME or Ang II compared to sham. Mice
treated with SN showed significantly increased cGMP content in sham and hypertensive
mice (Figure 5A). The treatment with SN significantly enhanced nitrite and nitrate levels
(marker of nitric oxide) in ischemic hind-limb from sham, while no effect was observed in
mice treated with L-NAME (Figure 5B). In mice infused with Ang II, sodium nitrite
treatment decreased nitrite and nitrate levels (Figure 5B).
Effects of Sodium Nitrite on Akt, eNOS and VEGF Receptor Phosphorylation in Ischemic
Hind-limb from Normotensive and Hypertensive Mice
Muscle lysates were immunoprecipitated with total anti-bodies for Akt, eNOS and VEGF
receptor and then blotted with specific antibodies for phosphorylated Akt, eNOS and VEGF
receptor phosphorylation. Akt and eNOS phosphorylation were significantly reduced in
hypertensive mice (L-NAME and Ang II) compared to sham, while total Akt and total eNOS
were similar in all groups (Figure 6A; B). In contrast, sham and hypertensive mice treated
with SN displayed an increase in Akt and eNOS phosphorylation compared to non-treated
mice (Figure 6A; B). Figure 6C illustrates in sham an increase in VEGF receptor
phsophorylation in response to SN; while total VEGF receptor expression was similar.
VEGF receptor phosphorylation and expression were down regulated in hypertensive
animals; and treatment with SN normalized VEGF receptor phosphorylation and expression
level (Figure 6C).
Discussion
The present study provides evidence supporting the beneficial effect of sodium nitrite (SN)
as a therapy to improve neovascularization and eventually blood flow recovery in the
ischemic hind-limb of normotensive and hypertensive mice.
It is well established that nitric oxide (NO) is an important regulator of vascular
homeostasis.[24,23,14,46] Nitric oxide is an autocrine and paracrine signaling molecule
with a very short lifetime.[15] Importantly, NO can also be stabilized in blood and tissue by
oxidation to nitrate and nitrite and can then be reduced back to NO under physiological and
pathological conditions.[19] In most hypertensive animal models, the bioavailability of NO
is markedly reduced mainly because of an increase in oxidative stress.[35,9]
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Hypertension was induced by either chronic inhibition of endothelial NO-synthesis (eNOS)
or infusion of Angiotensin II (Ang II).[18,20] The treatment of hypertensive mice with the
SN significantly lowered systolic blood pressure, whereas no effect was observed in sham
animals. Our data are in agreement with previous results showing that nitrite therapy
reduced pulmonary hypertension and hypertension-induced by L-NAME.[58,34,27] These
data strongly suggest the beneficial therapeutic role of nitrite in the reduction of
hypertension.
Femoral artery ligation was performed in all groups of mice. After two weeks, angiogenesis
and blood flow recoveries were greater in sham compared to hypertensive mice indicating
an alteration in angiogenesis development. These data are in agreement with previous
studies, showing that neovascularization was altered in hypertensive animal models.
[22,33,56] Angiotensin II has a differential effect on angiogenesis. A non-hypertensive dose
was shown to promote angiogenesis,[53,38] while hypertensive doses of Ang II reduce
angiogenesis as reported in the present and previous studies.[56,36] These data indicate that
the physiological effects of Ang II is to enhance angiogenesis whereas, the pathological
effect is to reduce angiogenesis. Sham and hypertensive mice treated with SN displayed
normalization in hind-limb vascularization associated with 100% blood flow recovery. It
was reported that normotensive mice treated with SN had more rapid restoration of blood
flow in the ischemic hind-limb.[32] These findings are similar to our results, suggesting that
continuous nitrite therapy is an effective strategy for enhancing vascularization and
eventually tissue perfusion. It has reported that aldosterone inhibits angiogenesis in response
to ischemia.[31] Indeed in the present study infusion of Ang II and L-NAME both support
increases in aldosterone levels.[42,47] The beneficial effect of sodium nitrite therapy could
be through the inhibition of aldosterone secretion or through down stream signaling to
aldosterone. Future studies are needed to demonstrate the relationship between sodium
nitrite and aldosterone in terms of neovascularization in response to ischemia.
To extend our data on the effect of sodium nitrite therapy by its conversion into nitric oxide
in our model, mice were treated with allopurinol, an inhibitor of xanthine-oxido-reductase
that reduces nitrite to nitric oxide. Allopurinol did not alter systolic blood pressure in L-
NAME and Ang II groups treated with sodium nitrite (data not shown). The inhibition of
xanthine-oxido-reductase or VEGF receptor prevents neovascularization in hypertensive
mice treated with sodium nitrite. These data indicate that the beneficial effect of sodium
nitrite is to enhance neovascularization in response to ischemia is mediated by xanthine-
oxido-reductase and VEGF receptor. We do not have direct evidence to show reduced
nitrite-nitric oxide formation in the tissues, but indirect evidence is supported by the
attenuation in ischemia-induced neovascularization in the presence of allopurinol.
The occurrence of vascular rarefaction has been well recognized in hypertensive patients
and animal models.[44,45,4] Our data suggest that ischemic hind-limb from mice treated
with L-NAME or Ang II display a significant reduction in capillary density compared to
sham. Sham and hypertensive mice treated with SN show a significant increase in capillary
density, indicating that SN is a potent promoter of vascular growth.
It is well established that NO acts through two distinctive signaling pathways, either
modulating protein function by S-nitrosation or via binding to the heme of guanylate
cyclase, the principal NO receptor. Previous studies show that NO is critical in the process
of vascularization.[39,16] In the present study, we demonstrated that cGMP, the downstream
signaling mediator of NO, was reduced in hypertensive mice compared to sham suggesting
that the NO pathway is impaired in hypertension, as previously reported.[9,41] The sham
and hypertensive mice treated with SN had significantly enhanced cGMP levels in the
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ischemic hind-limb. These data are not in agreement with previous studies, showing no
change in cGMP levels in mice treated with nitrite.[32,10]
We used another strategy to determine that increased NO was present in the ischemic hind-
limb of mice treated with SN. We measured nitrite and nitrate content in ischemic hind-limb
muscle from all mice. These results revealed a significant increase in nitrite and nitrate
content in sham mice treated with sodium nitrite. Surprisingly, ischemic hind-limb muscle
from mice infused with L-NAME did not show an effect, while Ang II group had a high
level of nitrite and nitrate content compared to sham and the group of mice treated with L-
NAME. In addition, Ang II-induced hypertensive mice treated with SN displayed a reduced
level of nitrite and nitrate content compared to Ang II alone. Therefore, it is important to
determine in the future whether Ang II and L-NAME could increase nitrite and nitrate
content through the induction of iNOS as previously reported.[1]
To emphasize the role of the NO pathway, we measured the phosphorylation of Akt, eNOS
and the VEGF receptor. Western blot analysis and immunoprecipitation studies revealed that
Akt, eNOS and VEGR phosphorylation were significantly reduced in ischemic hind-limb
from hypertensive mice compared to sham. These data are in agreement with previous
studies and suggest that Akt/eNOS/VEGF receptor phosphorylation pathway is impaired in
hypertension.[55,28] Hypertension has a differential effect on Akt/eNOS and VEGR
expression. Our data show that Akt and eNOS expression were similar in all groups, while
VEGFR expression was significantly reduced in hypertensive mice. Sham and hypertensive
mice treated with SN had restored expression and phosphorylation of Akt/eNOS and
VEGFR. These results are with agreement in the concept that Akt/eNOS and VEGFR are
important factors in angiogenesis.[5,17]
In this study, we demonstrated that sodium nitrite treatment accelerates angiogenesis and
eventually blood flow recovery in the ischemic hind-limb from normotensive and
hypertensive mice, by modulating the eNOS, Akt and VEGF receptor pathways. These data
provide a new insight in the knowledge of the therapeutic effect of sodium nitrite in the
induction of angiogenesis in ischemic tissue, in hypertension.
Clinical Perspective
Arterial hypertension is a progressive disease associated with endothelial dysfunction, and is
a major risk factor for coronary artery disease and subsequent myocardial infarction. Thirty
five to fifty five percent of patients with peripheral artery disease are hypertensive. It has
been shown that chronic sodium nitrite therapy augments ischemia-induced angiogenesis
and arteriogenesis in normotensive mice. In the present study, we demonstrated that
hypertensive mice treated with sodium nitrite have significantly reduced systolic blood
pressure and accelerates angiogenesis and blood flow recovery, probably mediated through
VEGF/eNOS/Akt and cGMP pathway. Our data suggest that sodium nitrite could provide
novel treatment for arterial hypertension and ischemic diseases by enhancing
neovascularization.
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Figure 1.
Effect of sodium nitrite (SN) treatment on blood pressure in normotensive (sham, n=10) and
hypertensive mice induced by chronic infusion of angiotensin II (Ang II, n=10) or L-NAME
treatment, n=10; *P < 0.05 for Ang II or L-NAME vs. Ang II + SN or L-NAME + SN; #P <
0.05 for Ang II and L-NAME vs. sham, sham + SN, L-NAME + SN, Ang II + SN; &P<0.05
for L-NAME + SN or Ang II + SN vs. sham with and without SN.
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Figure 2.
Blood flow analysis in the hind-limb of hypertensive (angiotensin II “Ang II” or L-NAME)
and normotensive mice (sham) treated with or not treated with sodium nitrite (SN); 2A:
Blood flow measured with MoorLDI-Laser in all groups (sham ± SN, Ang II ± SN and L-
NAME ± SN) before and just after surgery, and once a week for 2 weeks (this image is
representative of n=10); 2B: Alternative strategy for measuring Blood flow with MoorLDI-
Laser in all groups (sham ± SN, Ang II ± SN and L-NAME ± SN) before and just after
surgery, and once a week for 2 weeks; n=10; *P < 0.05 for sham + SN, Ang II + SN and L-
NAME + SN vs. sham; $P < 0.05 statistically significant for sham + SN, Ang II + SN and L-
NAME + SN vs. Ang II or L-NAME; #P<0.05 for sham + SN, L-NAME + SN, Ang II + SN
vs. L-NAME or Ang II; 2C–D: Blood flow measurements in hypertensive mice treated with
sodium nitrite and allopurinol (xanthine-oxido-reductase inhibitor, 100 mg/kg, i.p.) or
SU-5416 (VEGF receptor antagonist, 50 mg/kg, i.p.).
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Figure 3.
Microangiography determined at the end of the treatment period in all groups (sham ± SN,
Ang II ± SN and L-NAME ± SN). Contrast media (barium sulfate, 1 g/ml) was injected into
the abdominal aorta, and then angiogram from of the right and left hind-limb was assessed
with digital X-ray transducer acquired images. Images were then assembled to obtain a
complete view of the hind-limb vasculature; image is representative of n=5.
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Figure 4.
A: Example of overlapping immunostaining image for Von willebrand Factor (green arrow),
α-actin (red arrow), Dapi (blue arrow), and over-lap between Von willebrand and α-actin
(yellow arrow) in mouse hind-limb; B: Amplification of a portion from image A; C: Effect
of sodium nitrite (SN) treatment on the capillary density in sham and hypertensive mice
induced by chronic infusion of angiotensin II (Ang II) or L-NAME. Capillary density was
assessed by von Willebrand immunostaining, n=5; *P < 0.05 for sham vs. L-NAME
treatment and Ang II; #P < 0.05 for sham, L-NAME and Ang II treated with sodium nitrite
vs. sham, L-NAME and Ang II.
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Figure 5.
5A: Effect of sodium nitrite (SN) on cGMP level in ischemic hind-limb muscle from sham ±
SN and hypertensive mice induced by chronic infusion of angiotensin II (Ang II) ± SN or L-
NAME ± SN, n=5; *P < 0.05 for sham vs. sham + SN; #P < 0.05 for L-NAME vs. L-NAME
+ SN; $P < 0.05 for Ang II vs. Ang II + SN; 5B: Effect of sodium nitrite (SN) on nitrite
(white square) and nitrate (grey square) levels in ischemic hind-limb from sham ± SN and
hypertensive mice induced by chronic infusion of angiotensin II (Ang II) ± SN or L-NAME
treatment ± SN, n=5; *P < 0.05 for ischemic sham vs. non-ischemic and ischemic + SN; #P
< 0.05 for Ang II vs. Ang II + SN.
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Figure 6.
Effect of sodium nitrite (SN) treatment on Akt/eNOS and VEGF receptor expression in
ischemic hind-limb from sham and hypertensive mice. 6A: Immunoprecipitation, Western
blots analysis and quantitative data showing phosphorylated and expression of Akt in all
groups (sham ± SN, Ang II ± SN and L-NAME ± SN), n=5; *P < 0.05 for sham vs. sham +
SN; #P < 0.05 for L-NAME vs. L-NAME + SN; $P < 0.05 for Ang II or Ang II + SN vs.
sham (total expression of Akt was similar in all groups); 6B: Immunoprecipitation, Western
blots analysis and quantitative data showing phosphorylated and total expression of eNOS in
all groups (sham ± SN, Ang II ± SN and L-NAME ± SN), n=5; *P < 0.05 for sham vs. sham
+ SN; #P < 0.05 for L-NAME vs. L-NAME + SN; $P < 0.05 for Ang II or Ang II + SN vs.
sham (total expression of eNOS was similar in all groups); 6C: Immunoprecipitation and
Western blots analysis and quantitative data showing phosphorylated, expression of VEGF
receptor (VEGFR) in all groups (sham ± SN, Ang II ± SN and L-NAME ± SN), n=5; *P <
0.05 for sham vs. sham + SN; #P < 0.05 for L-NAME vs. L-NAME + SN; $P < 0.05 for Ang
II or Ang II + SN vs. sham.
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